Mepolizumab (Nucala) for the treatment of severe asthma

Introduction

The drug mepolizumab (trade name: Nucala) has been approved in Germany since December 2015 for the treatment of severe refractory eosinophilic asthma in adults. The drug can be used as an additional treatment if the treatment so far – for instance, with high-dose corticosteroids and long-acting beta2 agonists – is no longer effective enough. Since August 2018, mepolizumab has also been approved for use in children over the age of 6 and in teenagers.

The airways of people with are constantly inflamed. When the mucous membranes of the bronchi come into contact with certain irritants, the airways may contract and become narrow. Symptoms include episodes or "attacks" of wheezing, coughing and shortness of breath that can be treated with a number of medications.

Severe refractory eosinophilic is a type of in which patients – despite receiving treatment – have a high risk of asthma attacks that need to be treated in hospital. Eosinophilic granulocytes are immune system cells. In this type of , patients have an increased number of these cells in their blood and phlegm.

Mepolizumab is an antibody against a hormone that is part of the . It is meant to reduce the in the by reducing the number of eosinophilic granulocytes.

Application

Mepolizumab is injected into the upper arm, the thigh, or the stomach. The dose used depends on the patient’s age:

  • Teenagers over the age of 12 and adults receive 100 mg of mepolizumab every four weeks.
  • Children over the age of 6 receive 40 mg of mepolizumab every four weeks.

Other treatments

The patients receive individually tailored treatment depending on the type and severity of their . If the treatment isn't effective enough, the dose can be increased or several medications can be combined. In that case, drugs such as corticosteroids, tiotropium bromide, long-acting bronchodilators, or omalizumab are options.

Assessment

In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether mepolizumab has any advantages or disadvantages for people with severe refractory eosinophilic when compared with the current standard treatments.

But the manufacturer hasn't yet submitted any suitable data – either for children and teenagers or for adults.

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of mepolizumab (Nucala) for children, teenagers and adults.

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Mepolizumab – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A16-03. April 28, 2016. (IQWiG reports; Volume 385).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Mepolizumab – Addendum to Commission A16-03. Dossier assessment; Commission A16-33. June 29, 2016. (IQWiG reports; Volume 407).

Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Mepolizumab – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-58. December 20, 2018. (IQWiG reports; Volume 703)

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on January 17, 2019
Next planned update: 2022

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.